| Literature DB >> 28742152 |
Bartłomiej Salamaga1,2, Tomasz K Prajsnar1,3,4, Ana Jareño-Martinez1,2, Joost Willemse5, Martin A Bewley1,3, Françoise Chau6, Tassadit Ben Belkacem1,2, Annemarie H Meijer5, David H Dockrell1,3, Stephen A Renshaw1,3,4, Stéphane Mesnage1,2.
Abstract
Enterococcus faecalis is an opportunistic pathogen frequently isolated in clinical settings. This organism is intrinsically resistant to several clinically relevant antibiotics and can transfer resistance to other pathogens. Although E. faecalis has emerged as a major nosocomial pathogen, the mechanisms underlying the virulence of this organism remain elusive. We studied the regulation of daughter cell separation during growth and explored the impact of this process on pathogenesis. We demonstrate that the activity of the AtlA peptidoglycan hydrolase, an enzyme dedicated to septum cleavage, is controlled by several mechanisms, including glycosylation and recognition of the peptidoglycan substrate. We show that the long cell chains of E. faecalis mutants are more susceptible to phagocytosis and are no longer able to cause lethality in the zebrafish model of infection. Altogether, this work indicates that control of cell separation during division underpins the pathogenesis of E. faecalis infections and represents a novel enterococcal virulence factor. We propose that inhibition of septum cleavage during division represents an attractive therapeutic strategy to control infections.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28742152 PMCID: PMC5542707 DOI: 10.1371/journal.ppat.1006526
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 1E. faecalis expressing atlB under the PatlA promoter forms cell chains.
A. Western blot detection of His-tagged AtlA and AtlB proteins expressed under the control of the atlA (PatlA) or atlB (PatlB) promoters. Various amounts of exponentially growing cultures were harvested and total extracts corresponding to mixtures of broken cells and supernatants were analyzed by Western blot using anti-His antibodies. The faint band corresponding to AtlB-His is indicated by an arrowhead. B. Comparison of median forward scattered (FSC) light values corresponding to the cell chain lengths of WT, ΔatlA and PatlB::atlB-his strains; ****P<0.0001; n = 3; NS, P>0.05; n = 3.
Fig 2Truncation of AtlA N-terminal domain enhances septum cleavage activity in vitro.
A. SDS-PAGE analysis of purified recombinant proteins: lane 1, full-length AtlATEV (residues 53–737) corresponding to the mature protein (without the signal peptide), with a TEV site between domains 1 and 2; lane 2, TEV protease (TEV); lane 3, TEV digestion product of AtlATEV (AtlATEV+TEV); lane 4, AtlA truncated of its N-terminal domain (AtlAΔN). The amino acid sequences between N-terminal (orange) and catalytic (grey) domains in AtlA and AtlATEV are described. The TEV cleavage site is boxed. B. Comparison of specific enzymatic activities of AtlA and AtlAΔN in vitro using whole PG sacculi as a substrate; **P = 0.0018; n = 9. C. Flow cytometry analysis of septum cleavage activity of recombinant full-length AtlA and the N-terminally truncated variant (AtlAΔN). Activity is expressed as a percentage of the median forward scattered (FSC) light value corresponding to cell chains formed by the atlA mutant (ΔatlA) used as a substrate; ***P = 0.0008; n = 3.
Fig 3E. faecalis strains expressing N-terminally truncated AtlA form shorter cell chains.
A. Schematic representation of AtlA variants produced by recombinant E. faecalis JH2-2 derivatives. AtlAWT, full-length AtlA; AtlAΔN, AtlA truncated from the N-terminal domain; AtlA1-4, AtlA truncated from the two C-terminal LysM modules; AtlA1-4ΔN, AtlA1-4 truncated from the N-terminal domain. Blue, signal peptide; orange, N-terminal domain; green, catalytic domain; red, LysM domain. B. Comparison of median forward scattered (FSC) light values corresponding to the cell chain lengths of WT, atlAΔN, atlA1-4 and atlA1-4ΔN strains; **P = 0.0015; n = 3; ***P = 0.0001; n = 3. See also S2 Fig.
Fig 4E. faecalis strains lacking AtlA glycosylation form shorter cell chains.
A. Schematic representation of the atlATEV allele produced by E. faecalis. B. Metal affinity purification of cell surface associated His-tagged AtlA extracted with 8M urea. Two bands indicated by arrowheads were detected on a Coomassie-stained SDS-PAGE (lane 1); the upper band (72 kDa) corresponds to full-length AtlA proteins and the lower band to AtlA without the N-terminal domain (62 kDa). A clear signal corresponding to glycosylated full length AtlA (lane 2) was detected using the ECL glycoprotein detection kit (GE Healthcare). C. Exponentially growing cells from a culture expressing AtlATEV were resuspended in buffer in the absence (-) or presence (+) of TEV protease to cleave the N-terminal domain of AtlA. Solubilized proteins were recovered by centrifugation, loaded on an SDS-PAGE and transferred on nitrocellulose to detect glycosylated proteins. Two independent cultures treated with the TEV protease were analysed in parallel. In both cases, a glycosylated polypeptide with the expected molecular weight for the N-terminal domain (see Fig 2A) was detected while no signal was observed in the negative control. When a similar experiment was repeated with protein extracts from a ΔgtfAB mutant, no glycosylated protein was detected, indicating that this operon is involved in the post translational modification of AtlA. D. Comparison of median forward scattered (FSC) light values corresponding to the cell chain lengths of WT, ΔgtfAB, atlA1-4, atlA1-4ΔgtfAB, ΔatlA and ΔatlAΔgtfAB strains.
Fig 5AtlA N-acetylglucosaminidase activity is not essential for septum cleavage.
A. Schematic representation of AtlA variants expressed by recombinant E. faecalis JH2-2 derivatives. All strains were constructed by allele exchange to express AtlA variants under the control of the atlA promoter (arrow). Two restriction sites (NcoI, N and BglII, B) flanking the region encoding the catalytic domain were introduced by site-directed mutagenesis. The resulting allele in strain atlA* encodes an AtlA protein with eleven modified amino-acids (see supplementary S3 Fig). The NcoI-BglII fragment encoding AtlA N-acetylglucosaminidase activity was replaced with a fragment encoding the N-acetylmuramidase activity of E. faecalis AtlB to generate strain atlAAtlB, the amidase activity of S. aureus Atl to generate strain atlAAmi or the endopeptidase activity of Streptococcus thermophilus Cse to generate strain atlACse. B. E. faecalis peptidoglycan bonds cleaved by the catalytic domains of E. faecalis AtlA and AtlB, S. aureus AtlA and S. thermophilus Cse. C. Comparison of median forward scattered (FSC) light values corresponding to the cell chain lengths of WT, atlA*, atlAAtlB, atlAAmi, atlACse. and ΔatlA. All median FSC values were significantly different from the median FSC value from the ΔatlA strain (**P<0.01; n = 3).
Fig 6Contribution of the LysM domain to septum cleavage.
A. Schematic representation of AtlA and AtlB derivatives expressed and purified to test their septum cleavage activity. Full-length AtlA and AtlB (without signal peptides), as well as their counterparts with LysMB (AtlAB) or LysMA (AtlBA) domains, were expressed in E. coli. B. SDS-PAGE of AtlA (lane 1), AtlAB (lane 2), AtlB (lane 3) and AtlBA (lane 4) samples showing that all proteins were purified to homogeneity. C. Flow cytometry analysis of septum cleavage activity of recombinant proteins in vitro using OG1RF ΔatlA cell chains as a substrate (see materials and methods). The Di50 (Dechaining index) value corresponds to the amount of enzyme in pmoles that is able to decrease the median FSC value of ΔatlA cell chains by 50% in 15 minutes at 37°C. D. Schematic representation of atla locus in E. faecalis JH2-2 and isogenic derivatives producing AtlA with a C-terminal LysM domain containing a variable number of LysM repeats (6 in WT; 5 in atlA1-5; 4 in atlA1-4; 3 in atlA1-3; 2 in atlA1-2; 1 in atlA1). E. Comparison of median forward scattered (FSC) light values corresponding to the cell chain lengths of WT, atlA1-5, atlA1-4, atlA1-3, atlA1-2, atlA1 and ΔatlA strains. P values and significance corresponding to comparisons with the ΔatlA strain are indicated.
Fig 7E. faecalis long cell chains are less virulent in the zebrafish model of infection and more prone to phagocytosis than diplococci.
A. Survival of zebrafish larvae (n>20) following infection with E. faecalis OG1RF (WT) and atlA isogenic deletion mutant before (ΔatlA) and after (ΔatlAS) sonication to disperse long chains. Statistical significance was determined by Log-rank test; **P = 0.0011; *** P = 0.0002; NS, P>0.05. B. Quantification of E. faecalis uptake by zebrafish phagocytes. Embryos were infected with 1,200 E. faecalis cells expressing GFP and fixed in 4% paraformaldehyde 1.5h post infection. Phagocytes were immunolabelled using rabbit anti L-plastin antibodies and detected with goat anti-rabbit antibodies conjugated to Alexafluor 647. Fluorescent bacteria and phagocytes were imaged by scanning confocal microscopy. The area of GFP fluorescence signal outside and inside phagocytes was measured using a dedicated Fiji plugin. The ratio of GFP fluorescence area outside to inside phagocytes was used to quantify bacterial uptake. Phagocytosis was significantly higher for long chains (ΔatlA) when compared to their sonicated counterparts (ΔatlAS) (**P = 0.0098) or the wild-type cells (*P = 0.0438). No difference in uptake was found between short chains corresponding to the wild-type or sonicated ΔatlA mutant (NS, P>0.05). Representative images of phagocytes (magenta) following infection with ΔatlA, sonicated ΔatlAS and wild-type OG1RF cells shown. Phagocytes labeled with L-plastin appear in magenta, GFP-producing bacteria in green. Scale bar is 20μm. C. Survival of phagocyte-depleted zebrafish larvae (n>20) following injection with E. faecalis OG1RF (WT) or ΔatlA. D. Pairwise comparisons of phagocytosis indexes corresponding to E. faecalis OG1RF and ΔatlA uptake by human monocyte-derived macrophages (MDM). Statistical significance was determined by paired t-test; ΔatlA cells were more efficiently phagocytosed by MDM than WT cells (**P = 0.0024; n = 7).
Bacterial strains and plasmids used in this study.
| Strains, plasmids | Relevant properties or genotype | Source or reference |
|---|---|---|
| OG1RF | Plasmid-free, virulent laboratory strain isolated from the oral cavity | [ |
| OG1RF | OG1RF producing the GFP encoded by pMV158 | [ |
| OG1RFΔ | OG1RF mutant harboring a deletion in | This work |
| OG1RFΔ | OG1RF Δ | This work |
| JH2-2 | Plasmid-free laboratory strain | [ |
| Δ | JH2-2 mutant harboring an in-frame deletion of | [ |
| P | JH2-2 producing a C-terminally his-tagged AtlB under the | This work |
| P | JH2-2 producing a C-terminally his-tagged AtlA (native locus) | This work |
| P | JH2-2 producing a C-terminally his-tagged AtlB (native locus) | This work |
| | JH2-2 producing AtlA without its N-terminal domain | This work |
| | JH2-2 | This work |
| Δ | JH2-2 derivative with an in-frame deletion of the | This work |
| Δ | JH2-2 Δ | This work |
| | JH2-2 | This work |
| | JH2-2 producing AtlA with a catalytic domain flanked by NcoI and BamHI sites | This work |
| | JH2-2 | This work |
| | JH2-2 | This work |
| | JH2-2 | This work |
| | JH2-2 producing AtlA lacking the last C-terminal LysM repeat | This work |
| | JH2-2 producing AtlA lacking the last 2 C-terminal LysM repeats | This work |
| | JH2-2 producing AtlA lacking the last 3 C-terminal LysM repeats | This work |
| | JH2-2 producing AtlA lacking the last 4 C-terminal LysM repeats | This work |
| | JH2-2 producing AtlA lacking the last 5 C-terminal LysM repeats | This work |
| TG1 | Host for plasmid propagation | Lab stock |
| TG1(RepA) | TG1 derivative producing RepA for pGhost propagation at 37°C | P. Serror |
| BL21(DE3) | BL21 derivative for protein expression | Novagen |
| pGhost9 | Thermosensitive plasmid for gene replacement in | [ |
| pMV158 | Replicative plasmid for constitutive | [ |
| pGHH0799 | pGhost9 derivative used to construct strain OG1RF Δ | [ |
| pGABhis | pGhost9 derivative used to construct strain P | This work |
| pGAAhis | pGhost9 derivative used to construct strain P | This work |
| pGBBhis | pGhost9 derivative used to construct strain P | This work |
| pGDN | pGhost9 derivative used to construct strain | This work |
| pGgtfAB | pGhost9 derivative used to construct strain Δ | This work |
| pGatlA1-5 | pGhost9 derivative used to construct strain | This work |
| pGatlA1-4 | pGhost9 derivative used to construct strain | This work |
| pGatlA1-3 | pGhost9 derivative used to construct strain | This work |
| pGatlA1-2 | pGhost9 derivative used to construct strain | This work |
| pGatlA1 | pGhost9 derivative used to construct strain | This work |
| pGatlA* | pGhost9 derivative used to construct strain | This work |
| pGatlA-Cse | pGhost9 derivative used to construct strain | This work |
| pGatlA-AtlB | pGhost9 derivative used to construct strain | This work |
| pGatlA-Ami | pGhost9 derivative used construct strain | This work |
| pET2818 | pET28a derivative for overexpression of His-tagged proteins (AmpR) | [ |
| pET-AtlATEV | pET2818 encoding AtlA with a TEV site upstream of the catalytic domain | This work |
| pET-AtlB | pET2818 encoding AtlB | This work |
| pET-AtlAB | pET2818 encoding AtlA with a LysM domain replaced by that of AtlB | This work |
| pET-AtlBA | pET2818 encoding AtlB with a LysM domain replaced by that of AtlA | This work |
a AmpR, resistant to ampicillin; ErmR, resistant to erythromycin